# US 2012/0252693 A1 · Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252693 A1
- Document ID: US20120252693A1
- Status: Published application
- Kind: A1
- Application number: 13/508,262
- Filed: 2010-11-04
- Published: 2012-10-04
- Earliest claimed: 2009-11-04
- Assignees: Diamir, LLC
- Inventors: Samuil R. Umansky; Kira S. Sheinerman
- Web page: https://patentgrep.com/patent/US20120252693A1

## CPC

- C12Q 1/68: involving nucleic acids
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Described are methods for detection of neuronal pathologies using quantitative analysis in bodily fluids of synapse and/or neurite small RNAs and application of these methods to early diagnosis and monitoring of neurodegenerative diseases and other neurological disorders.

## Claims

### Claim 1

A method for diagnosing a neuronal pathology in a subject, which comprises:
a. determining the level of at least one synapse or neurite small RNA in a bodily fluid sample from the subject;
b. comparing the level of the small RNA in the bodily fluid sample from the subject with a control level of the small RNA, and
c. (i) identifying the subject as being afflicted with the neuronal pathology when the level of the small RNA in the bodily fluid sample from the subject is increased as compared to the control or (ii) identifying the subject as not being afflicted with the neuronal pathology when the level of the small RNA in the bodily fluid sample from the subject is not increased as compared to the control.

### Claim 2

A method for diagnosing a neuronal pathology in a subject, which comprises:
a. determining the level of a synapse or neurite small RNA in a bodily fluid sample from the subject;
b. determining the level of a neuronal body small RNA in a bodily fluid sample from the subject;
c. determining the ratio of the levels of the small RNAs determined in steps (a) and (b);
d. comparing the ratio of the levels of the small RNAs determined in step (c) with a corresponding control ratio, and
e. (i) identifying the subject as being afflicted with the neuronal pathology when the ratio of the levels of the small RNAs determined in step (c) is higher than the corresponding control ratio or (ii) identifying the subject as not being afflicted with the neuronal pathology when ratio of the levels of the small RNAs determined in step (c) is not higher than the corresponding control ratio.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the neuronal pathology is associated with a neurodegenerative disease.

### Claim 4 (depends on 3)

The method of claim 3, wherein the neurodegenerative disease is a member selected from the group consisting of Alzheimer's disease (AD), Parkinson's disease (PD), Lewy Body dementia, Huntington's disease (HD), frontotemporal dementia (FTD), vascular dementia, HIV Associated Neurocognitive Disorders (HAND), mild cognitive impairment (MCI), mixed dementia, Creutzfeldt-Jakob Disease (CJD), normal pressure hydrocephalus, Wernicke-Korsakoff syndrome, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), prion diseases, and different ataxias.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein the neuronal pathology is associated with an encephalopathy or neuropathy.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2, wherein the neuronal pathology is diagnosed prior to massive neuronal cell death characteristic of said pathology.

### Claim 7

A method for diagnosing Alzheimer's disease (AD) in a subject, which comprises:
a. determining the level of at least one synapse or neurite small RNA in a bodily fluid sample from the subject;
b. comparing the level of the small RNA in the bodily fluid sample from the subject with a control level of the small RNA, and
c. (i) identifying the subject as being afflicted with AD when the level of the small RNA in the bodily fluid sample from the subject is increased as compared to the control or (ii) identifying the subject as not being afflicted with AD when the level of the small RNA in the bodily fluid sample from the subject is not increased as compared to the control.

### Claim 8 (depends on 7)

The method of claim 7, wherein AD is diagnosed prior to massive neuronal cell death characteristic of AD.

### Claim 9

A method for diagnosing mild cognitive impairment (MCI) in a subject, which comprises:
a. determining the level of at least one synapse or neurite small RNA in a bodily fluid sample from the subject;
b. comparing the level of the small RNA in the bodily fluid sample from the subject with a control level of the small RNA, and
c. (i) identifying the subject as being afflicted with MCI when the level of the small RNA in the bodily fluid sample from the subject is increased as compared to the control or (ii) identifying the subject as not being afflicted with MCI when the level of the small RNA in the bodily fluid sample from the subject is not increased as compared to the control.

### Claim 10 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the small RNA is present in synapses.

### Claim 11 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the small RNA is present in spines.

### Claim 12 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the small RNA is present in axons.

### Claim 13 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the small RNA is present in dendrites.

### Claim 14 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the small RNA is miRNA.

### Claim 15 (depends on 14)

The method of claim 14, wherein the miRNA is a member selected from the group consisting of miR-7, miR-9, miR-9*, miR-25, miR-26a, miR-26b, miR-98, miR-124, miR-125b, miR-128, miR-132, miR-134, miR-138, miR-146, miR-182, miR-183, miR-200b, miR-200c, miR-213, miR-292-5p, miR-297, miR-322, miR-323-3p, miR-325, miR-337, miR-339, miR-345, miR-350, miR-351, miR-370, miR-425, miR-429, miR-433-5p, miR-446, miR-467, and miR-874.

### Claim 16 (depends on 14)

The method of claim 14, wherein the miRNA is a member selected from the group consisting of miR-7, miR-125b, miR-128, miR-132, miR-323-3p, miR-370, and miR-874.

### Claim 17 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the control level of the small RNA is the level of said small RNA in a similarly processed bodily fluid sample from an age-matched control subject.

### Claim 18 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the control level of the small RNA is the level of said small RNA in a similarly processed bodily fluid sample from the same subject obtained in the past.

### Claim 19 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the control level of the small RNA is a predetermined standard.

### Claim 20 (depends on 2)

The method of claim 2, wherein the neuronal body small RNA is miR-181a or miR-491-5p.

### Claim 21 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9 comprising determining the level of two or more synapse or neurite small RNAs.

### Claim 22 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, further comprising normalizing the level of the small RNA in the bodily fluid sample from the subject and in the control to the level of a small RNA which is not expressed in brain.

### Claim 23 (depends on 22)

The method of claim 22, wherein the small RNA which is not expressed in brain is miR-10b or miR-141.

### Claim 24 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the bodily fluid sample is blood plasma.

### Claim 25 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein the level of the small RNA is determined using a method selected from the group consisting of hybridization, RT-PCR, and sequencing.

### Claim 26 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, wherein, prior to step (a), the small RNA is purified from the bodily fluid sample.

### Claim 27 (depends on 1, 2, 7)

The method of any one of claim 1, 2, 7, or 9, further comprising the step of reducing or eliminating degradation of the small RNA.

### Claim 28

A method for monitoring development of a neuronal pathology in a subject, which comprises:
a. determining the level of at least one synapse or neurite small RNA in two or more bodily fluid samples from the subject, wherein the samples have been obtained at spaced apart time points, and
b. comparing the levels of the small RNA between the earlier obtained and later obtained bodily fluid sample(s).

### Claim 29 (depends on 28)

The method of claim 28, which further comprises (c) (i) determining that the development of the neuronal pathology in the subject is accelerated if the level of the small RNA is increased in the later obtained bodily fluid sample(s) as compared to the earlier obtained sample(s); (ii) determining that the neuronal pathology in the subject continues to develop at the same rate if the level of the small RNA is not changed in the later obtained bodily fluid sample(s) as compared to the earlier obtained sample(s), and (iii) determining that the development of the neuronal pathology in the subject is slowed down if the level of the small RNA is decreased in the later obtained bodily fluid sample(s) as compared to the earlier obtained sample(s).

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein the bodily fluid samples have been obtained within 1-48 months intervals.

### Claim 31

A method for monitoring the effectiveness of a treatment of a neuronal pathology in a subject, which comprises:
a. determining the level of at least one synapse or neurite small RNA in a bodily fluid sample from the subject obtained prior to initiation of the treatment;
b. determining the level of the small RNA in one or more bodily fluid sample(s) from the subject obtained in the course of or following the treatment, and
c. comparing the level of the small RNA determined in steps (a) and (b), and optionally between different samples in step (b).

### Claim 32 (depends on 31)

The method of claim 31, which further comprises (d) (i) determining that the treatment is effective if the level of the small RNA has decreased in the course of or following the treatment or (ii) determining that the treatment is not effective if the level of the small RNA has not decreased in the course of or following the treatment.

### Claim 33 (depends on 31, 32)

The method of claim 31 or 32, wherein the bodily fluid samples have been obtained within 1 week-12 months intervals.

### Claim 34 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein, the small RNA is present in synapses.

### Claim 35 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein, the mall RNA is present in spines.

### Claim 36 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein, the small RNA is present in axons.

### Claim 37 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein, the small RNA is present in dendrites.

### Claim 38 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein the small RNA is miRNA.

### Claim 39 (depends on 38)

The method of claim 38, wherein the miRNA is a member selected from the group consisting of miR-7, miR-9, miR-9*, miR-25, miR-26a, miR-26b, miR-98, miR-124, miR-125b, miR-128, miR-132, miR-134, miR-138, miR-146, miR-182, miR-183, miR-200b, miR-200c, miR-213, miR-292-5p, miR-297, miR-322, miR-323-3p, miR-325, miR-337, miR-339, miR-345, miR-350, miR-351, miR-370, miR-425, miR-429, miR-433-5p, miR-446, miR-467, and miR-874.

### Claim 40 (depends on 38)

The method of claim 38, wherein the miRNA is a member selected from the group consisting of miR-7, miR-125b, miR-128, miR-132, miR-323-3p, miR-370, and miR-874.

### Claim 41 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32 comprising determining the level of two or more synapse or neurite small RNAs.

### Claim 42 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein the bodily fluid sample is blood plasma.

### Claim 43 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein the level of the small RNA is determined using a method selected from the group consisting of hybridization, RT-PCR, and sequencing.

### Claim 44 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein, prior to step (a), the small RNA is purified from the bodily fluid sample.

### Claim 45 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, further comprising the step of reducing or eliminating degradation of the small RNA.

### Claim 46 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein the neuronal pathology is associated with a neurodegenerative disease.

### Claim 47 (depends on 46)

The method of claim 46, wherein the neurodegenerative disease is a member selected from the group consisting of Alzheimer's disease (AD), Parkinson's disease (PD), Lewy Body dementia, Huntington's disease (HD), frontotemporal dementia (FTD), vascular dementia, HIV Associated Neurocognitive Disorders (HAND), mild cognitive impairment (MCI), mixed dementia, Creutzfeldt-Jakob Disease (CJD), normal pressure hydrocephalus, Wernicke-Korsakoff syndrome, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), prion diseases, and different ataxias.

### Claim 48 (depends on 28, 29, 31)

The method of any one of claim 28, 29, 31, or 32, wherein the neuronal pathology is monitored prior to massive neuronal cell death characteristic of said pathology.
